Montalvo-Ortiz, Janitza L.
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Cheng, Zhongshan
Girgenti, Matthew J. http://orcid.org/0000-0003-1647-326X
Xu, Ke http://orcid.org/0000-0002-6472-7052
Zhang, Xinyu http://orcid.org/0000-0001-8154-9334
Gopalan, Shyamalika http://orcid.org/0000-0002-2608-8472
Zhou, Hang http://orcid.org/0000-0002-7694-6391
Duman, Ronald S. http://orcid.org/0000-0001-8690-8439
Southwick, Steven M.
Krystal, John H. http://orcid.org/0000-0001-6952-1726
Friedman, Matthew J.
Duman, Ronald S.
Girgenti, Matthew J.
Krystal, John H.
Montalvo-Ortiz, Janitza L.
Pietrzak, Robert H.
,
Funding for this research was provided by:
U.S. Department of Veterans Affairs (1IK2CX002095)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R21DA050160)
Article History
Received: 24 November 2021
Revised: 26 December 2021
Accepted: 14 January 2022
First Online: 17 February 2022
Competing interests
: The following competing interests for JHK: (1) Consultant: Note: The Individual Consultant Agreements listed below are less than $10,000 per year: AstraZeneca Pharmaceuticals; Biogen, Idec, MA; Biomedisyn Corporation; Bionomics, Limited (Australia); Concert Pharmaceuticals, Inc.; Heptares Therapeutics, Limited (UK); Janssen Research & Development; L.E.K. Consulting; Otsuka America Pharmaceutical, Inc.; Spring Care, Inc.; Sunovion Pharmaceuticals, Inc.; Takeda Industries; Taisho Pharmaceutical Co., Ltd; Scientific Advisory Board; Bioasis Technologies, Inc.; Biohaven Pharmaceuticals; Blackthorn Therapeutics, Inc.; Broad Institute of MIT and Harvard; Cadent Therapeutics; Lohocla Research Corporation; Pfizer Pharmaceuticals; Stanley Center for Psychiatric Research at the Broad Institute; (2) Stock: ArRETT Neuroscience, Inc.; Blackthorn Therapeutics, Inc.; Biohaven Pharmaceuticals Medical Sciences; Spring Care, Inc. Stock Options: Biohaven PharmaceuticalsMedical Sciences; (3) Income Greater than $10,000: Editorial BoardEditor—Biological Psychiatry; Patents and Inventions: Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in the treatment of schizophrenia. US Patent #:5,447,948. September 5, 1995; Vladimir, Coric, Krystal, John H, Sanacora, Gerard—Glutamate Modulating Agents in the Treatment of Mental Disorders US Patent No. 8,778,979 B2 Patent Issue Date: July 15, 2014. US Patent Application No. 15/695,164: Filing Date: 09/05/2017; Charney D, Krystal JH, Manji H, Matthew S, Zarate C., Intranasal Administration of Ketamine to Treat Depression United States Application No. 14/197,767 filed on March 5, 2014; United States application or Patent Cooperation Treaty (PCT) International application No. 14/306,382 filed on June 17, 2014; Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, Krystal, JH, Department of Veterans Affairs “Methods for Treating Suicidal Ideation”, Patent Application No. 14/197.767 filed on March 5, 2014 by Yale University Office of Cooperative Research; Arias A, Petrakis I, Krystal JH. Composition and methods to treat addiction; Provisional Use Patent Application no.61/973/961. April 2, 2014. Filed by Yale University Office of Cooperative Research; Chekroud, A., Gueorguieva, R., & Krystal, JH. “Treatment Selection for Major Depressive Disorder” [filing date 3rd June 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission by Yale University; Yoon G, Petrakis I, Krystal JH. Compounds, Compositions, and Methods for Treating or Preventing Depression and Other Diseases. U. S. Provisional Patent Application No. 62/444,552, filed on January10, 2017 by Yale University Office of Cooperative Research OCR 7088 US01; Abdallah, C, Krystal, JH, Duman, R, Sanacora, G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. U.S. Provisional Patent Application No. 047162-7177P1 (00754) filed on August 20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01. JG is named as an inventor on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. Other co-authors declare no completing interests.